bearish
Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome
792 Views03 Sep 2018 06:28
Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Innovent Biologics IPO First-Day: Take Money off the Table31 Oct 2018
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
- Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene02 Oct 2018
- BeiGene (6160 HK): On a Stronger Post-Listing Footing than Ascletis13 Aug 2018
- BeiGene IPO Preview: Lucrative Lifesavers31 Jul 2018
- Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation22 Jul 2018
x